M Humbert

Summary

Country: France

Publications

  1. ncbi Pulmonary arterial hypertension in patients treated by dasatinib
    David Montani
    Service de Pneumologie et Reanimation Respiratoire, Hopital Bicetre, 78 rue du General Leclerc, 94270 Le Kremlin Bicetre, France
    Circulation 125:2128-37. 2012
  2. ncbi Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension
    Peter Dorfmuller
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, F 94276, France
    Respir Res 12:119. 2011
  3. ncbi Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
    Barbara Girerd
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, F 94276, France
    Respir Res 11:73. 2010
  4. ncbi Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
    Christopher P Denton
    Centre for Rheumatology, Royal Free Campus, University College Medical School, London, NW3 2PF, UK
    Arthritis Res Ther 13:114. 2011
  5. ncbi [A critical analysis of survival in idiopathic pulmonary arterial hypertension]
    Marc Humbert
    Universite Paris Sud XI, Orsay, France
    Presse Med 39:1S41-5. 2010
  6. ncbi Mediators involved in HIV-related pulmonary arterial hypertension
    Marc Humbert
    UPRES EA2705 and INSERM U764, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    AIDS 22:S41-7. 2008
  7. ncbi Treatment of pulmonary arterial hypertension
    Marc Humbert
    Centre des Maladies Vasculaires Pulmonaires, , , , , Clamart, France
    N Engl J Med 351:1425-36. 2004
  8. ncbi Update in pulmonary arterial hypertension 2007
    Marc Humbert
    , , 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 177:574-9. 2008
  9. ncbi [Targeted immunologic therapies for severe asthma]
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, AP HP, Hopital Antoine Beclere, Universite Paris Sud, F 92140 Clamart, France
    Presse Med 37:173-81. 2008
  10. ncbi Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
    M Humbert
    Univ Paris Sud, Faculte de Medecine, Kremlin Bicetre, 2AP HP, Centre National de Référence de l Hypertension Pulmonaire Sévère, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Clamart, France
    Eur Respir Rev 19:59-63. 2010

Collaborators

Detail Information

Publications168 found, 100 shown here

  1. ncbi Pulmonary arterial hypertension in patients treated by dasatinib
    David Montani
    Service de Pneumologie et Reanimation Respiratoire, Hopital Bicetre, 78 rue du General Leclerc, 94270 Le Kremlin Bicetre, France
    Circulation 125:2128-37. 2012
    ..Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib...
  2. ncbi Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension
    Peter Dorfmuller
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, F 94276, France
    Respir Res 12:119. 2011
    ..The impact of OS on vascular remodeling in PH is still to be determined. We hypothesized, that augmented blood-flow could increase OS and might thereby contribute to DC/inflammatory cell-recruitment and smooth-muscle-cell-proliferation...
  3. ncbi Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
    Barbara Girerd
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, F 94276, France
    Respir Res 11:73. 2010
    ..A recent report has suggested that this may only be the case for females and that patients with missense mutations in BMPR2 gene have more severe disease than patients with truncating mutations...
  4. ncbi Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
    Christopher P Denton
    Centre for Rheumatology, Royal Free Campus, University College Medical School, London, NW3 2PF, UK
    Arthritis Res Ther 13:114. 2011
    ..Failure to take this into account may compromise progress in managing PAH in SSc...
  5. ncbi [A critical analysis of survival in idiopathic pulmonary arterial hypertension]
    Marc Humbert
    Universite Paris Sud XI, Orsay, France
    Presse Med 39:1S41-5. 2010
    ..Modern survival figures also highlight the relevance of lung transplantation in eligible PAH patients refractory to current best standard of care...
  6. ncbi Mediators involved in HIV-related pulmonary arterial hypertension
    Marc Humbert
    UPRES EA2705 and INSERM U764, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    AIDS 22:S41-7. 2008
    ..Recent results from studies into other potential mediators of PAH offer the possibility of new targets for therapy in this progressive and serious condition...
  7. ncbi Treatment of pulmonary arterial hypertension
    Marc Humbert
    Centre des Maladies Vasculaires Pulmonaires, , , , , Clamart, France
    N Engl J Med 351:1425-36. 2004
  8. ncbi Update in pulmonary arterial hypertension 2007
    Marc Humbert
    , , 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 177:574-9. 2008
  9. ncbi [Targeted immunologic therapies for severe asthma]
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, AP HP, Hopital Antoine Beclere, Universite Paris Sud, F 92140 Clamart, France
    Presse Med 37:173-81. 2008
    ..The first targeted treatment approved for severe difficult-to-control allergic asthma is an anti-IgE monoclonal antibody (omalizumab)...
  10. ncbi Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
    M Humbert
    Univ Paris Sud, Faculte de Medecine, Kremlin Bicetre, 2AP HP, Centre National de Référence de l Hypertension Pulmonaire Sévère, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Clamart, France
    Eur Respir Rev 19:59-63. 2010
    ..Further research into these similarities is needed to assist the development of targeted pharmacological therapies for patients with inoperable CTEPH and patients who have persistent pulmonary hypertension after endarterectomy...
  11. ncbi Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
    M Humbert
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur Respir J 36:549-55. 2010
    ..Survival of idiopathic, familial and anorexigen-associated PAH can be characterised by means of a novel risk-prediction equation using patients' characteristics at diagnosis...
  12. ncbi Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension
    Marc Humbert
    Universite Paris Sud 11, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique des Hopitaux de Paris, Clamart, France
    Vascul Pharmacol 49:113-8. 2008
    ..A greater understanding of the role of the endothelium in PAH will presumably facilitate the evolution of newer, targeted therapies...
  13. ncbi [Anti IgE antibodies for the treatment of difficult asthma]
    M Humbert
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    Rev Mal Respir 22:983-90. 2005
    ..It remains unknown whether the beneficial effects of omalizumab could be extended to patients with severe non allergic (so-called "intrinsic") asthma, a variant of the disease which is often difficult to control...
  14. ncbi Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival
    Marc Humbert
    Universite Paris Sud, Le Kremlin Bicetre, France AP HP Hôpital Antoine Béclère, Clamart, France
    Arthritis Rheum 63:3522-30. 2011
    ..However, little is known about the impact of detection programs on patients with SSc-PAH. This study was undertaken to assess the clinical characteristics of patients with SSc-PAH at diagnosis and their long-term outcomes...
  15. ncbi Inflammation in pulmonary arterial hypertension
    Laura C Price
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, France
    Chest 141:210-21. 2012
    ..The potential benefit of antiinflammatory therapies in iPAH is of importance and requires further study...
  16. ncbi Pulmonary arterial hypertension in France: results from a national registry
    Marc Humbert
    UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 173:1023-30. 2006
    ..Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend is for management in designated centers with multidisciplinary teams working in a shared-care approach...
  17. ncbi Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, Faculte de Medecine, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 92140 Clamart, France
    Circulation 122:156-63. 2010
    ..We conducted a study to characterize mortality in a multicenter prospective cohort of patients diagnosed with idiopathic, familial, or anorexigen-associated pulmonary arterial hypertension in the modern management era...
  18. ncbi Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
    R Souza
    Université Pains Sud, UPRES EA 2705 Pneumology Dept and French National Reference Centre for Pulmonary Hypertension, Antoine Beclere Hospital, Clamart, Paris, France
    Eur Respir J 31:343-8. 2008
    ..Therefore, the present authors conclude that fenfluramine exposure characterises a potent trigger for pulmonary arterial hypertension without influencing its clinical course...
  19. ncbi [Pulmonary artery hypertension associated with connective tissue diseases]
    O Sanchez
    Centre des Maladies Vasculaires Pulmonaires (UPRES EA 2705, , , 157 rue de la Porte de Trivaux, 92140 Clamart
    Presse Med 32:789-99. 2003
    ..IN PRACTICE: PH is a severe complication of connective tissue diseases. Early detection of this complication should allow an earlier and more aggressive therapeutic approach in these patients, before irreversible vascular lesions occur...
  20. ncbi Pulmonary veno-occlusive disease
    D Montani
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, Department of Pneumology and Intensive Care, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Eur Respir J 33:189-200. 2009
    ..Lung transplantation is the treatment of choice. Cautious use of specific PAH therapy can, however, be helpful in some patients...
  21. ncbi [Guidelines for the diagnosis and treatment of pulmonary hypertension]
    O Sanchez
    Service de Pneumologie et Soins Intensifs, Hopital Europeen Georges Pompidou, AP HP, Faculte de Medecine, Universite Paris Descartes, 20, rue Leblanc, 75015 Paris, France
    Rev Mal Respir 27:141-50. 2010
    ..A joint Task Force of the ESC and of the ERS has developed guidelines on the diagnosis and treatment of pulmonary hypertension (PH) to provide updated information on the management of patients with this condition...
  22. ncbi Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension
    F Perros
    UPRES EA2705, Service de Pneumologie, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Robinson, France
    Eur Respir J 29:937-43. 2007
    ..In conclusion, the current authors proposed that fractalkine may act as a growth factor for pulmonary artery smooth muscle cells. Chemokines may thus play a role in pulmonary artery remodelling...
  23. ncbi Risk factors for pulmonary arterial hypertension
    M Humbert
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Clin Chest Med 22:459-75. 2001
    ....
  24. ncbi [Treatments for pulmonary arterial hypertension.]
    D Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA2705, , , , , 157, rue de la Porte-de-Trivaux, 92140 Clamart, France
    Rev Med Interne 25:720-31. 2004
    ..FUTURE PROSPECTS AND PROJECTS: The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in our understanding of the mechanisms mediating pulmonary arterial hypertension...
  25. ncbi Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
    O Sitbon
    Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Thorax 60:1025-30. 2005
    ....
  26. ncbi Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
    D Montani
    Universite Paris Sud, Faculte de Medecine, Centre National de Référence de l Hypertension Pulmonaire Sévère, Service de Pneumologie et Reanimation Respiratoire, AP HP, INSERM U999, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 34:1348-56. 2009
    ..Cautious use of continuous intravenous epoprostenol improved clinical and haemodynamic parameters in PVOD patients at 3-4 months without commonly causing pulmonary oedema, and may be a useful bridge to urgent lung transplantation...
  27. ncbi [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma]
    M Humbert
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, , , AP-HOP, , 157 rue de la Porte-de-Trivaux, 92140 Clamart, France
    Rev Med Interne 28:S273-6. 2007
  28. ncbi Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension
    S Provencher
    Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur Respir J 32:393-8. 2008
    ..Improvement in exercise tolerance with chronic therapy is independently related to improvement in pulmonary haemodynamics measured in exercise but not in resting conditions...
  29. ncbi Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats
    J Le Pavec
    Hopital Marie Lannelongue, Universite Paris Sud, Le Plessis Robinson, France
    Eur Respir J 34:731-9. 2009
    ..Biliary cirrhosis induces pulmonary vasodilation that ameliorates MCT-induced PH and improves survival. Upregulation of inducible NO synthase and ET(B) receptor and downregulation of ET(A) receptor may be involved...
  30. ncbi [Treatment of pulmonary arterial hypertension]
    D Montani
    , , UPRES EA2705, , , AP-HP, Clamart
    Presse Med 34:1445-55. 2005
    ..The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in our understanding of the mechanisms mediating pulmonary arterial hypertension...
  31. ncbi Pulmonary arterial hypertension masquerading as severe refractory asthma
    L Achouh
    Universite Paris Sud 11, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 32:513-6. 2008
    ..The present observations add dilatation of the central pulmonary arteries with compression of the mainstem bronchi to the list of masqueraders of asthma in patients with pulmonary arterial hypertension...
  32. ncbi Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
    B Degano
    Department of Respiratory and Intensive Care Medicine, Universite Paris Sud 11, National Reference Centre for Pulmonary Arterial Hypertension, Institut Paris Sud Cytokines, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 33:92-8. 2009
    ..The present data confirm the long-term benefits of bosentan therapy in HIV-associated pulmonary arterial hypertension patients with improvements in symptoms, 6-min walk distance and haemodynamics, and with favourable overall survival...
  33. ncbi Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension
    B Sztrymf
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Assistance Publique, Hopitaux de Paris, 92140 Clamart, France
    Eur Respir J 35:1286-93. 2010
    ..Whether these parameters can guide therapy needs to be further investigated...
  34. ncbi [Postembolic pulmonary hypertension]
    X Jais
    Centre de Référence de l Hypertension Artérielle Pulmonaire, Unité Propre de Recherche de l Enseignement Supérieur EA2705, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    Rev Mal Respir 24:497-508. 2007
    ....
  35. ncbi Splenectomy and chronic thromboembolic pulmonary hypertension
    X Jais
    UPRES EA 2705, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Thorax 60:1031-4. 2005
    ....
  36. ncbi [Pulmonary arterial hypertension]
    D Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA2705, , , , Assistance Publique, , Clamart, France
    Rev Mal Respir 22:651-66. 2005
    ..The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in our understanding of the mechanisms mediating pulmonary arterial hypertension...
  37. ncbi Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
    H Nunes
    UPRES EA 2363, Service de Pneumologie, Hopital Avicenne, Assistance Publique Hopitaux de Paris, Universite Paris 13, 125 rue de Stalingrad, 93009 Bobigny, France
    Thorax 61:68-74. 2006
    ..Pulmonary hypertension (PH) is a rare complication of sarcoidosis, although it is not uncommon in advanced disease...
  38. ncbi Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    O Sitbon
    Hopital Antoine Beclere, Service de Pneumologie, Clamart, France
    Eur J Clin Invest 36:25-31. 2006
    ..Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD)...
  39. ncbi Pathobiology of pulmonary hypertension. The role of platelets and thrombosis
    P Herve
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine Béclère et Hôpital Marie Lannelongue, Universite Paris Sud, Clamart, France
    Clin Chest Med 22:451-8. 2001
    ..Activated platelets interact with the PA wall and may contribute to the functional and structural alterations of pulmonary vessels by releasing vasoactive factors and mitogenic mediators...
  40. ncbi Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease
    D Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, , , , , Clamart, France
    Eur Respir J 26:969-72. 2005
    ..In conclusion, further studies should help in characterising the best candidates for anti-inflammatory treatment in the setting of pulmonary arterial hypertension...
  41. ncbi Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases
    P Guilpain
    Department of Clinical Hematology, Hopital Necker Enfants Malades, Assistance Publique Hopitaux de Paris, Universite Paris V, Paris, France
    Respiration 76:295-302. 2008
    ..Some studies have suggested an association between PH and myeloproliferative diseases (MPD)...
  42. ncbi [Pulmonary arterial hypertension due to tumor emboli]
    J M Dot
    Centre national de référence de l hypertension pulmonaire, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Rev Mal Respir 24:359-66. 2007
    ..Pulmonary arterial hypertension (PAH) is rare in the presence of malignancy and tumour embolisation is one of several possible pathological mechanisms...
  43. ncbi Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
    M Humbert
    , Clamart, France
    Allergy 60:309-16. 2005
    ..Omalizumab is effective and should be considered as add-on therapy for patients with inadequately controlled severe persistent asthma who have a significant unmet need despite best available therapy...
  44. ncbi [Clinical, haemodynamic and genetic features of familial pulmonary arterial hypertension.]
    B Sztrymf
    , UPRES EA 2705, Centre des Maladies Vasculaires Pulmonaires, , , , Paris, France
    Rev Mal Respir 21:909-15. 2004
    ..We do not propose that familial PAH should be treated any differently from the idiopathic form. Genetic counselling will need to be developed in line with the progress being made in the understanding of this condition...
  45. ncbi [Investigation of pulmonary hypertension]
    D Natali
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 92141 Clamart Cedex, France
    Rev Pneumol Clin 64:151-61. 2008
    ..Characterization of PH is essential in the management of PH because it determines the appropriate treatment: an etiological treatment in passive, obstructive or hypoxemic PH, or vasodilatator and antiproliferative therapies in PAH...
  46. ncbi [Pulmonary hypertension complicating systemic diseases other than connective tissue diseases]
    O Sanchez
    Centre des Maladies Vasculaires Pulmonaires (UPRES EA 2705, , , 157 rue de la Porte de Trivaux, 92140 Clamart
    Presse Med 32:800-3. 2003
    ..The physiopathological mechanisms responsible are unclear (specific parenchymal fibrosis, isolated vascular involvement...). Globally, available treatments are disappointing...
  47. ncbi The association between resting and mild-to-moderate exercise pulmonary artery pressure
    K Whyte
    Service des Explorations Fonctionnelles, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92 140, Clamart, France E mail
    Eur Respir J 39:313-8. 2012
    ..The clinical relevance of such findings deserves further long-term follow-up studies...
  48. ncbi [Genetics of pulmonary arterial hypertension: recent data and practical applications]
    B Sztrymf
    UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, France
    Rev Mal Respir 22:796-805. 2005
    ..Beside idiopathic PAHT and that associated with other conditions, a familial form has been identified...
  49. ncbi Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
    M Humbert
    Hopital Antoine Beclere, Assistance Publique, Hopitaux de Paris, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92140, Clamart, France
    Eur Respir J 24:353-9. 2004
    ..Several cases of early and late major complications were reported. Additional information is needed to evaluate the risk/benefit ratio of combined bosentan-epoprostenol therapy in pulmonary arterial hypertension...
  50. ncbi Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension
    N Gambaryan
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, France
    Eur Respir J 37:1392-9. 2011
    ..This study offers important pathophysiological insights into the role of haematopoietic c-kit+ progenitors in hypoxia-induced vascular remodelling and may have therapeutic implications for PH...
  51. ncbi Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre
    D Montani
    Univ Paris Sud, Faculte de Medecine, Kremlin Bicetre, AP HP, Centre National de Référence de l Hypertension Pulmonaire Sévère, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Clamart
    Eur Respir Rev 18:272-90. 2009
    ..Appropriate investigation and therapeutic strategies for patients with chronic thromboembolic disease and PH that is associated with congenital heart disease, pulmonary veno-occlusive disease and systemic sclerosis are also highlighted...
  52. ncbi Update on the roles of distal airways in asthma
    P R Burgel
    Hopital Cochin, AP HP, Universite Paris Descartes, Paris, France
    Eur Respir Rev 18:80-95. 2009
    ..However, available studies have not yet demonstrated that extra-fine inhaled medications offer increased benefit compared with usual aerosols in asthmatic patients...
  53. ncbi Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension
    F Perros
    UPRES EA2705, Service de Pneumologie, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, France
    Eur Respir J 29:462-8. 2007
    ..The results support the concept that immature dendritic cells accumulate in remodelled pulmonary vessels and hence could be involved in the immunopathology of pulmonary hypertension...
  54. ncbi Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension
    L C Price
    Faculte de Medecine, University Paris Sud, Kremlin Bicetre, France
    Eur Respir J 35:1294-302. 2010
    ..Emergency procedures, major surgery and long operations were associated with increased risk...
  55. ncbi [The relationship between inflammation and symptoms in asthma]
    D Montani
    Universite Paris Sud 11, Hopital Antoine Beclere, Clamart, France
    Rev Mal Respir 25:933-51. 2008
    ..A French expert group has undertaken a study of the association between inflammation and asthma symptoms by carrying out a critical review of the international literature...
  56. ncbi Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
    L C Price
    Faculte de Medecine, Universite Paris Sud, Paris, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 37:813-22. 2011
    ..In this model, mechanisms may involve reduction of IL-6-expressing inflammatory cells, restoration of pulmonary BMPR2 expression and reduced proliferation of vascular smooth muscle cells...
  57. ncbi Occult alveolar haemorrhage in pulmonary veno-occlusive disease
    A Rabiller
    Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie, , , Clamart, France
    Eur Respir J 27:108-13. 2006
    ..It was concluded that occult alveolar haemorrhage is a common feature of pulmonary veno-occlusive disease. Detecting occult alveolar haemorrhage may be of interest in the diagnostic approach of pulmonary veno-occlusive disease...
  58. ncbi Chemokine receptor expression on allergen-specific T cells in asthma and allergic bronchopulmonary aspergillosis
    G Garcia
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, France
    Allergy 62:170-7. 2007
    ..Allergic bronchopulmonary aspergillosis (ABPA) is a rare variant of severe asthma resulting from hypersensitivity to Aspergillus fumigatus (Asp f) present in the airways...
  59. ncbi Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma
    M Humbert
    Universite Paris Sud 11, Service de Pneumologie, Hopital Antoine Beclere, Clamart, France
    Allergy 63:592-6. 2008
    ..However, as exacerbations are relatively infrequent, assessment of efficacy on day-to-day symptoms is warranted...
  60. ncbi Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics
    M Humbert
    Universite Paris Sud 11, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique des Hopitaux de Paris, 157 rue de la Porte de Trivaux, Clamart 92140, France
    Allergy 64:1194-201. 2009
    ..We hypothesized that c-kit and PDGF receptor inhibition may decrease bronchial inflammation and interfere with airway remodeling, which are crucial features of severe asthma...
  61. ncbi Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis
    M Humbert
    Université Paris Sud 11 Hôpital Antoine Béclère, Clamart, France
    Allergy 64:81-4. 2009
    ..However, despite being shown to often co-exist, they are typically treated as independent conditions. Omalizumab, an anti-IgE antibody, has proven effective in the treatment of both asthma and rhinitis...
  62. ncbi BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
    M Humbert
    Service de Pneumologie, Hĵpital Antoine Béclère, Clamart, France
    Eur Respir J 20:518-23. 2002
    ....
  63. ncbi [Adult asthma exacerbations in questions]
    D Montani
    Service de Pneumologie et de Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud 11, AP HP, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Rev Mal Respir 27:1175-94. 2010
    ..The efficacy of inhaled corticosteroids has been demonstrated on reduction of the number of exacerbations and the number of asthma-related deaths. This treatment is cost-effective, especially in terms of reduction of exacerbations...
  64. ncbi [Pulmonary hypertension and obesity]
    B Sztrymf
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Hopital Antoine Béclere AP HP, Universite Paris Sud, 157, rue de la Porte de Trivaux, 92140 Clamart
    Rev Pneumol Clin 58:104-10. 2002
    ..There is also a possible relationship with left ventricular failure, hypoxemia, and other respiratory disorders (including obstructive sleep apnea), hypothyroidism, and thomboembolism...
  65. ncbi Primary pulmonary hypertension: Current therapy
    Olivier Sitbon
    , Pulmonary Vascular Center, , , , Clamart, France
    Prog Cardiovasc Dis 45:115-28. 2002
    ..In such patients with severe pulmonary hypertension refractory to medical therapy, atrioseptostomy and lung transplantation can be indicated...
  66. ncbi Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
    Olivier Sitbon
    Service de Pneumologie et Reanimation, UPRES EA 2705 on Pulmonary Vascular Diseases, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Am Coll Cardiol 40:780-8. 2002
    ..We sought to determine the factors associated with long-term survival in patients with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion...
  67. ncbi [HIV-related pulmonary arterial hypertension]
    L Savale
    Universite Paris Sud, Faculte de Medecine, 94276 Kremlin Bicêtre, France Centre de référence de l hypertension pulmonaire sévère, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, AP HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France Inserm U999, hypertension artérielle pulmonaire, physiopathologie et innovation thérapeutique, 92350 Le Plessis Robinson, France
    Rev Mal Respir 29:491-500. 2012
    ..Other PAH-specific therapies remain to be evaluated. The advent of HAART associated with the development of PAH-specific therapies has improved the prognosis of patients HIV-related PAH, with a survival rate of about 70% at 3 years...
  68. ncbi [Treatment for pulmonary arterial hypertension under the new French hospital financing system. Recommendations of the Pulmonary Vascular Diseases Working Group of the French Society of Pulmonary Medicine]
    O Sitbon
    Centre de référence national sur l HTAP, Service de Pneumologie et Reanimation, UPRES EA2705, Universite Paris Sud, Hopital Antoine Beclere, AP HP, Clamart
    Presse Med 34:1456-64. 2005
    ..The Pulmonary Vascular Diseases working group of the French Society of Pulmonary Medicine has developed guidelines for the best practices in use of these drugs...
  69. ncbi [Hilar adenopathy compressing the pulmonary arteries in the course of sarcoidosis]
    A Dumas de la Roque
    Service de Radiologie, Hopital Antoine Beclere, Clamart, France
    Rev Mal Respir 24:1151-4. 2007
    ..In pulmonary sarcoidosis, vascular involvement is usually limited to the small and medium-sized vessels. Enlarged hilar lymph nodes are usually considered to be soft and hence unlikely to cause pressure on adjacent bronchi or blood vessels...
  70. ncbi [Pulmonary hypertension: from genetics to treatments]
    M Humbert
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Réseau INSERM AFM sur l hypertension artérielle pulmonaire, Hopital Antoine Beclere, Clamart
    Rev Pneumol Clin 60:196-201. 2004
    ..Inhaled iloprost and type 5 phosphodiesterase inhibitors should be evaluated for this indication. Lung transplantation is reserved for patients unresponsive to medical treatment...
  71. ncbi [Intrinsic asthma]
    M Humbert
    Service de Pneumologie et Reanimation Respiratoire, Clinique de l Asthme, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux, 92140 Clamart
    Rev Pneumol Clin 59:84-8. 2003
    ....
  72. ncbi Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension
    Dermot S O'Callaghan
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicêtre F 94276, France
    Respir Med 104:S74-80. 2010
    ..This review details the rationale for the different combination strategies and examines the clinical evidence in favour of some of the approaches that have been evaluated...
  73. ncbi Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension
    Hilario Nunes
    UPRES 2705, Centre des Maladies Vasculaires Pulmonaires, , , , , Clamart, France
    Am J Respir Crit Care Med 167:1433-9. 2003
    ..These results suggest that patients with severe human immunodeficiency virus-associated PAH should be considered for long-term epoprostenol infusion in association with CART...
  74. ncbi Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia
    Saadia Eddahibi
    INSERM U651, Departement de Physiologie, Hôpital H Mondor, AP HP, Creteil, France
    Circulation 113:1857-64. 2006
    ..We investigated the role of pulmonary microvascular endothelial cells (P-ECs) in controlling PA-SMC growth...
  75. ncbi Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
    David Montani
    Universite Paris Sud, Orsay, France
    Adv Ther 26:813-25. 2009
    ..Due to their clinical effectiveness, tolerance profile, and their oral administration, sildenafil and tadalafil are two of the recommended first-line therapies for PAH patients in World Health Organization functional classes II or III...
  76. ncbi Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension
    Ségolène Cabrol
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation, AP HP, Universite Paris Sud, Hopital Antoine Beclere, Clamart, France
    J Heart Lung Transplant 26:357-62. 2007
    ..Vascular remodeling lesions can be found in lungs of patients with CTEPH. Little is known about epoprostenol therapy in inoperable distal CTEPH patients...
  77. ncbi Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology
    David Montani
    Universite Paris Sud 11, UPRES EA 2705, Centre des Maladies Vasculaires Pulmonaires, Paris, France
    Medicine (Baltimore) 87:220-33. 2008
    ..Clinical outcomes of PVOD patients were worse than those of PAH patients...
  78. ncbi Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation
    Benjamin Sztrymf
    Universite Paris Sud 11, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 177:1377-83. 2008
    ..Germline mutations in the gene encoding for bone morphogenetic protein receptor 2 (BMPR2) are a cause of pulmonary arterial hypertension (PAH)...
  79. ncbi Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation
    Barbara Girerd
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, 92140 Clamart, France
    Am J Respir Crit Care Med 181:851-61. 2010
    ..Activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) mutation is a cause of hereditary hemorrhagic telangiectasia (HHT) and/or heritable pulmonary arterial hypertension (PAH)...
  80. ncbi Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
    S Provencher
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, AP HP Université Paris Sud IX, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 27:114-20. 2006
    ..The lack of chronotropic response may reflect the loss in normal physiological reserve in more unwell patients...
  81. ncbi Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH
    D Montani
    Universite Paris Sud, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Hopital Antoine Beclere, France
    Eur Respir Rev 18:42-6. 2009
    ....
  82. ncbi Predicting and evaluating response to omalizumab in patients with severe allergic asthma
    J Bousquet
    Service de Pneumologie, Hopital Arnaud de Villeneuve, 371 Avenue du Doyen G Giraud, Montpellier 34295, France
    Respir Med 101:1483-92. 2007
    ..Omalizumab is a monoclonal antibody indicated for treatment of severe persistent allergic asthma inadequately controlled despite optimal controller therapy. We investigated whether patient selection could be targeted further...
  83. ncbi Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?
    Dermot S O'Callaghan
    Faculte de Medecine, Universite Paris Sud, 94276 Kremlin Bicêtre, France
    Presse Med 40:e65-78. 2011
    ..This review summarises the epidemiologic, clinico-pathologic and imaging characteristics of PVOD in the setting of CTD and discusses potential management approaches...
  84. ncbi Pulmonary veno-occlusive disease: advances in clinical management and treatments
    Alice Huertas
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, F 94276, France
    Expert Rev Respir Med 5:217-29; quiz 230-1. 2011
    ..PVOD is characterized by a poor prognosis and the possibility of developing severe pulmonary edema with specific PAH therapy. Lung transplantation remains the treatment of choice...
  85. ncbi Pulmonary veno-occlusive disease: recent progress and current challenges
    David Montani
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, INSERM U999, Centre National de Référence de l Hypertension Pulmonaire Sévère, 92140 Clamart, France
    Respir Med 104:S23-32. 2010
    ..Unfortunately, the long term effects of these agents are variable and lung transplantation remains the treatment of choice...
  86. ncbi [Treatment of pulmonary arterial hypertension in 2011: what's new since the 2009 ERS/ESC guidelines?]
    Laurent Savale
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, France
    Presse Med 40:1S54-60. 2011
    ..Finally, clinical trials evaluating combinations of treatments have shown encouraging results...
  87. ncbi CX(3)C chemokine fractalkine in pulmonary arterial hypertension
    Karl Balabanian
    INSERM U131, UPRES EA2705, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Institut Paris Sud sur les Cytokines, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Am J Respir Crit Care Med 165:1419-25. 2002
    ..Fractalkine mRNA and protein product are expressed in pulmonary artery endothelial cells. We conclude that inflammatory mechanisms involving chemokine fractalkine and its receptor CX(3)CR1 may have a role in the natural history of PAH...
  88. ncbi Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure
    Arnaud Resten
    Department of Radiology, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Radiology 222:782-8. 2002
    ..To correlate pretherapeutic thin-section computed tomographic (CT) findings in patients with pulmonary hypertension with the risk of fatality with treatment with epoprostenol...
  89. ncbi [Pulmonary arterial hypertension]
    Xavier Jais
    Centre de référence de l hypertension pulmonaire sévère, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 92141 Clamart Cedex, France
    Rev Prat 58:1997-2010. 2008
    ..The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in our understanding of the mechanisms mediating pulmonary arterial hypertension...
  90. ncbi Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension
    Olivier Sitbon
    Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 170:1212-7. 2004
    ....
  91. ncbi Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis
    Bruno Degano
    Service de Pneumologie, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Chest 137:1297-303. 2010
    ..Because they are generally excluded from randomized controlled trials, little is known about these patients...
  92. ncbi Cellular and molecular pathobiology of pulmonary arterial hypertension
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, UPRES EA2705, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Am Coll Cardiol 43:13S-24S. 2004
    ..Disordered proteolysis of the extracellular matrix is also evident in PAH. Future studies are required to find which if any of these abnormalities initiates PAH and which ones are best targeted to cure the disease...
  93. ncbi Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults
    Denis Chemla
    Paris Sud University EA4046, Medical Intensive Care Unit, Paris, France
    Chest 135:760-8. 2009
    ..Our study evaluated the accuracy and precision of various empirical formulas relating mPAP and sPAP in resting adults...
  94. ncbi [Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension]
    Olivier Sitbon
    Centre de référence national de l HTAP, Service de Pneumologie, UPRES EA2705, Hopital Antoine Beclere, AP HP, Université Paris XI Sud, 92141 Clamart Cedex, France
    Rev Prat 58:2011-8. 2008
    ..However, their prognosis differs greatly: it is poor in scleroderma, and much better in congenital heart diseases...
  95. ncbi Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents
    Mohamed Izikki
    INSERM U841, Faculte de Medecine, 8 Avenue du General Sarrail, 94010 Creteil, France
    J Clin Invest 119:512-23. 2009
    ..Thus, endothelial FGF2 is overproduced in IPH and contributes to SMC hyperplasia in IPH, identifying FGF2 as a promising target for new treatments against PH...
  96. ncbi Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences
    David Montani
    Universite Paris Sud 11, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Clamart, France
    Semin Respir Crit Care Med 30:411-20. 2009
    ..Lung transplantation remains the treatment of choice, but cautious use of specific PAH therapy can be helpful in select patients while awaiting this intervention...
  97. ncbi [Pulmonary hypertension associated with systemic sclerosis]
    Olivier Sanchez
    , UPRES EA 2705 Maladies vasculaires pulmonaires, , 157, rue de la Porte-de-Trivaux, 92140 Clamart, France
    Ann Med Interne (Paris) 153:250-9. 2002
    ..Novel therapies including oral, sub-cutaneous or inhaled stable prostacyclin analogues and endothelin receptor antagonists are currently evaluated in large placebo-controlled trials...
  98. ncbi HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era
    Bruno Degano
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Clamart, France
    AIDS 24:67-75. 2010
    ....
  99. ncbi [Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis]
    David Montani
    Univ Paris Sud, Faculte de Medecine, Kremlin Bicetre, F 94276, France
    Presse Med 39:134-43. 2010
    ..In patients with the most severe disease, the prudent use of continuous intravenous epoprostenol, can serve as bridge-therapy while awaiting a lung transplant...